Latest Biopharmaceutical Manufacturing News

Page 1 of 1

IDT Australia Lifts FY26 Revenue Forecast 16.5% with Sharper EBITDA Losses

IDT Australia boosts its FY26 revenue guidance to $16.8 million, anticipating a substantial narrowing of EBITDA losses to under $1 million, driven by strong demand and cost efficiencies.

Ada Torres

21 July 2026

Top